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http://dx.doi.org/10.1016/j.ccr.2012.10.023SUMMARYHyperactive PI3K/mTOR signaling is prevalent in human malignancies and its inhibition has potent antitumor
consequences. Unfortunately, single-agent targeted cancer therapy is usually short-lived. We have discov-
ered a JAK2/STAT5-evoked positive feedback loop that dampens the efficacy of PI3K/mTOR inhibition.
Mechanistically, PI3K/mTOR inhibition increased IRS1-dependent activation of JAK2/STAT5 and secretion
of IL-8 in several cell lines and primary breast tumors. Genetic or pharmacological inhibition of JAK2 abro-
gated this feedback loop and combined PI3K/mTOR and JAK2 inhibition synergistically reduced cancer
cell number and tumor growth, decreased tumor seeding andmetastasis, and also increased overall survival
of the animals. Our results provide a rationale for combined targeting of the PI3K/mTOR and JAK2/STAT5
pathways in triple-negative breast cancer, a particularly aggressive and currently incurable disease.INTRODUCTION
Detailed understanding of the genetic abnormalities that drive
subsets of cancer has led to the development of highly specific
inhibitors targeting key oncogenic pathways. The clinical
efficacy and low toxicity of some of these mechanism-based
therapies raised hopes for a new era in the treatment of
cancer (Haber et al., 2011; Sellers, 2011). This is illustrated by
several therapeutic successes, including imatinib in chronic
myelogenous leukemia carrying the BCR-ABL fusion gene
(O’Brien et al., 2003), and targeting V600EmutantB-RAF inmeta-
static melanoma (Flaherty et al., 2010). At the same time, it
became evident that genetic and adaptive resistance are
major obstacles in translating therapeutic efficacy into curative
cancer therapy due to the evolutionary nature of cancer and the
instable genome of some cancers. A thorough understanding of
the ‘‘wiring diagram’’ of cancer cells and themechanismsof resis-
tance to targeted therapy is of paramount importance for design-
ing multidrug combinations (Haber et al., 2011; Sellers, 2011).Significance
The PI3K/mTOR pathway is very often subverted during tumo
Twenty-six inhibitors of this pathway are currently in clinical
triple-negative breast cancer, we have discovered that PI3K/m
JAK2/STAT5. This induces secretion of the pro-metastatic cyto
completing the loop. Notably, inhibition of JAK2 abrogated t
increased overall survival of the animals. These data suggest
andprovidea rationale for combined inhibitionof thePI3K/mTO
796 Cancer Cell 22, 796–811, December 11, 2012 ª2012 Elsevier IncThe phosphatidylinositol 3-kinase (PI3K) signaling axis is vital
for cell metabolism, proliferation, survival, andmotility (Engelman
et al., 2006). Class I PI3Ks phosphorylate phosphatidylinositol-
4,5-bisphosphate and generate phosphatidylinositol-3,4,5-
trisphosphate downstream of growth factor receptors and G
protein-coupled receptors. This leads to activation of several
kinases, including protein kinase B (PKB/AKT), mammalian tar-
get of rapamycin (mTOR), and p70 ribosomal protein S6 kinase
(S6K) (Engelmanet al., 2006). Studies inDrosophilamelanogaster
and inmammalian cells have revealed a PI3K regulatory negative
feedback in which activation of S6K dampens IGF1-receptor
(IGF-1R)/PI3K signaling via suppression of IRS1 (Harrington
et al., 2004; Haruta et al., 2000; Radimerski et al., 2002).
The PI3K signaling cascade is one of the most frequently hy-
peractivated pathways in human cancer (Samuels et al., 2004).
Not surprisingly, different classes of PI3K, AKT, andmTOR inhib-
itors have been developed and 26 compounds are presently in
clinical trials (Engelman, 2009; Sheppard et al., 2012). Early
results show limited efficacy of allosteric mTOR complex 1rigenesis and contributes to numerous hallmarks of cancer.
trials. Using various cell lines and primary tumor models of
TOR inhibition elicits a positive feedback loop by activating
kine IL-8, which in turn feeds back into JAK2/STAT5, thereby
his feedback, reduced tumor seeding and metastasis and
IL-8 as a predictor of the efficacy of PI3K/mTOR inhibition
RandJAK2/STAT5pathways in triple-negativebreast cancer.
.
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JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibition(mTORC1) inhibition, most likely because it abrogates S6K-
mediated negative feedback, leading to reactivation of PI3K/
AKT signaling (O’Reilly et al., 2006). Similarly, allosteric AKT inhi-
bition reactivates several RTKs that attenuate the beneficial
effect of the inhibitor (Chandarlapaty et al., 2011). These studies
stress the urgent need to identify mechanisms of resistance to
PI3K pathway inhibition in order to rationally design optimal
drug combinations.
The Janus family of kinases (JAKs) and their associated signal
transducers and activators of transcription (STATs) also play
a key role in cancer. Activation of JAKs/STATs stimulates cell
proliferation, differentiation, migration, and survival (Harry
et al., 2012). The JAK/STAT pathway is activated upon binding
of hormones and cytokines (e.g., prolactin and interleukins) to
their receptors. In neoplasia, the ligands are secreted by cancer
cells and/or by cells from the tumor microenvironment (Bissell
and Radisky, 2001). JAKs/STATs can also be activated by
gain-of-function mutations like the JAK2 V617F mutation in
myeloproliferative neoplasms, for which JAK2 inhibitors have
shown promising activity (Harrison et al., 2012).
Given the many inhibitors of the PI3K pathway currently being
evaluated, we sought to understand the effects of inhibiting this
pathway on signaling in order to anticipate potential mecha-
nisms of resistance. We assessed the effects of PI3K/mTOR
inhibition in triple-negative breast cancer (TNBC), which is char-
acterized by the absence of expression of estrogen and proges-
terone as well as ERBB2/HER2 receptors, is associated with
a dismal prognosis, and still lacks effective targeted therapies
(Hudis and Gianni, 2011).
RESULTS
PI3K/mTOR Inhibition Activates JAK2/STAT5
As PI3K/mTOR is a crucial oncogenic signaling node, its inhibi-
tion would be expected to activate compensatory mechanisms.
To test this, we assessed the effects of inhibiting the PI3K/mTOR
pathway in PTEN-deficient MDA-MB468 (MDA468) and RAS-
mutatedMDA-MB231 LM2 (MDA231 LM2) human breast cancer
cells and in the mouse breast cancer line 4T-1. Single doses of
BEZ235, a dual PI3K/mTOR inhibitor currently in clinical trials
(Maira et al., 2008; Serra et al., 2008), were applied and the phos-
phorylation levels of several signaling proteins measured.
BEZ235 reduced pAKT and completely blocked pS6 levels up
to 20 hr in vitro and in vivo (Figure 1A; Figure S1A available on-
line). Surprisingly, we also detected considerable upregulation
of pJAK2 and pSTAT5, but not consistently of pSTAT3, after
BEZ235 treatment (Figures 1A and S1A).
To elucidate which arm of the dual PI3K/mTOR inhibitor
BEZ235 was responsible for the observed crosstalk to JAK2/
STAT5, we applied the pan-PI3K inhibitor BKM120 and the
mTORC1 inhibitor RAD001. Individual inhibition of either PI3K
and mTORC1 upregulated pJAK2 and pSTAT5. Notably,
although RAD001 readily activated JAK2/STAT5 after 4 hr treat-
ment, BKM120 induced JAK2/STAT5 only after 8 hr (Figure S1B).
Both JAK1 and JAK2 signal to STAT5 and STAT3 depending
on cell type and the receptor with which they are associated
(Desrivie`res et al., 2006). Thus, we examined whether JAK1
and/or JAK2 are responsible for STAT5 activation upon PI3K/
mTOR inhibition. siRNA depletion of each JAK isoform revealedCanthat JAK2 activates STAT5 while JAK1 is upstream of STAT3
in our models (Figure 1B). Furthermore, siRNA depletion and
inhibition of JAK2 by the JAK2-specific inhibitor NVP-BSK805
(Baffert et al., 2010) both counteracted the BEZ235-mediated
upregulation of pSTAT5 (Figure 1C). As found in other models
(Andraos et al., 2012), JAK2 inhibition by NVP-BSK805 efficiently
blocked phosphorylation of STAT5 but did not reduce phosphor-
ylation of JAK2.
Combined PI3K/mTOR and JAK2 Inhibition Induces
Cell Death
Notably, we observed rapid recovery of pAKT after treatment
with BEZ235 in all models, whereas pS6 remained inhibited
(Figures 1A and S1A). We found that PHLPP, the phosphatase
that targets Ser473 of AKT (Gao et al., 2005), was downregulated
after 8 hr of BEZ235 treatment (Figure S2A). In addition,
mTORC2 inhibition by siRNA-mediated depletion of RICTOR
combined with BEZ235 treatment prevented the recovery of
pAKT Ser473 (Figure S2B). As JAK2 is known to activate PI3K
(Jin et al., 2008; Yamauchi et al., 1998), it was conceivable that
BEZ235-induced JAK2 activation contributed to AKT reactiva-
tion. To test this, we examined whether combined inhibition of
JAK2 and PI3K/mTOR prolongs inhibition of pAKT. Indeed,
although blocking JAK2 alone did not impact on pAKT levels,
the combination of BEZ235 and NVP-BSK805 prolonged pAKT
suppression (Figure 2A).
To determine effects of blocking JAK2/STAT5 signaling on cell
viability, we treated breast cancer lines with NVP-BSK805 or
BEZ235 alone or in combination at concentrations that inhibit
their respective targets. Although NVP-BSK805 alone had no
impact on cell viability, it significantly decreased the number of
living cells when combined with BEZ235. Combination of NVP-
BSK805 andBEZ235 also significantly reduced colony formation
capacity compared with DMSO or the single drug treatments
(Figure 2B). Similar results were obtained with combinations of
a doxycycline-inducible shRNAagainst JAK2or siRNA-mediated
depletion of STAT5A and B and BEZ235 treatment (Figure S2C).
To assess effects on cell death, we performed FACS analysis
of propidium iodide- and/or AnnexinV-stained cells (Figures 2C,
left panel, and S2D). Addition of NVP-BSK805 to BEZ235-
treated cells resulted in a 25%–41%decrease in cells in S-phase
and an 1.8-fold increase in cells in sub-G1 (Figure S2D). Inter-
estingly, cell death was not induced by individual treatments but
increased significantly after combined inhibition of PI3K/mTOR
and JAK2/STAT5 (Figure 2C, left panel). Immunoblotting re-
vealed upregulation and increased electrophoretic mobility of
the BH3-only protein BIM and, thus, its activation following treat-
ment with NVP-BSK805 alone or in combination with BEZ235
(Figure 2C, right panel). Because BIM is inhibited by ERK1/2
(Ley et al., 2003), we assessed ERK1/2 phosphorylation levels
in cells treated with BEZ235 and/or NVP-BSK805 but found no
consistent changes in pERK1/2 (Figure S2E). It was reported
previously that activation of BIM and downregulation of the
pro-survival BCL2-family member MCL1 are both required for
induction of cell death (Certo et al., 2006). In line with this, immu-
noblotting showed degradation ofMCL1 only in cells treatedwith
both BEZ235 and NVP-BSK805 (Figure 2C, right panel). Consis-
tently, we found an increase in cleaved PARP only after com-
bined BEZ235/NVP-BSK805 treatment (Figure 2C, right panel).cer Cell 22, 796–811, December 11, 2012 ª2012 Elsevier Inc. 797
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Figure 1. Dual PI3K/mTOR Inhibition by BEZ235 Activates JAK2/STAT5
(A) Immunoblots of lysates from breast cancer cells grown as monolayer cultures or as xenografts and treated with BEZ235 (BEZ). Mice bearing xenografts were
treated with vehicle (VHC) or 30mg/kg BEZ and dissected as indicated. The numbers indicate the ratios of pSTAT5/STAT5 asmeasured by densitometry. pJAK2
levels were measured in triplicate by ELISA and normalized to total JAK2 levels (y axis). ERK2 levels were used as a loading control.
(B) Immunoblots of lysates from breast cancer cells in which JAK2 and/or JAK1 were depleted by siRNA (siJAK). siNT, nontargeting control siRNA.
(C) Immunoblots of lysates from 8 hr BEZ-treated MDA468 cells in which JAK2/STAT5 signaling was blocked by JAK2 siRNA (left panel) or by the JAK2-specific
inhibitor NVP-BSK805 (BSK) (right panel). ELISA data are means ± SD (n = 3).
See also Figure S1.
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JAK2/STAT5 Activation Dampens PI3K/mTOR InhibitionGiven the involvement of the PI3K/AKT pathway in the regula-
tion of several BH3-only proteins (Parcellier et al., 2008), we
assessed the levels and activation states of BAD, BCL2,
and BCL-XL. Both BCL2 and BCL-XL declined upon JAK2 inhi-
bition or the combination treatment, whereas inactive pBAD
decreased following PI3K/mTOR inhibition or the combination
treatment (Figure 2C, right panel). These data indicate a pivotal
involvement of decreased MCL1 in cell death induction by the
combination of BEZ235 and NVP-BSK805.
Dual PI3K/mTOR Inhibition Triggers Secretion of IL-8
To determine whether the observed activation of JAK2/STAT5
upon BEZ235 treatment occurs via secretion of a soluble factor,
we collected conditioned medium from cells treated for 20 hr
with BEZ235, applied this to untreated cells, and lysed them
1 hr later. Medium supplemented with BEZ235 was used as
a control. pJAK2 and pSTAT5 were both upregulated upon incu-
bation with the conditioned medium compared with the control798 Cancer Cell 22, 796–811, December 11, 2012 ª2012 Elsevier Inctreatments, suggesting that a soluble factor mediated activation
of JAK2/STAT5 (Figure 3A).
As JAKs are crucial transducers of cytokine signaling, we
analyzed cytokine profiles after BEZ235 treatment, either in
supernatants of cultured cells or lysates of tumor xenografts.
Considerable changes in several cytokines were found, the
most consistent being upregulation of IL-8 (Figure 3B).
To gain further insight into the kinetics of this response, we
performed ELISA for IL-8 on supernatants of cells treated with
BEZ235 (Figure 3C, left). A significant increase in IL-8 secretion
was found after 20 hr of treatment. This secretion pattern was
mirrored by upregulation of IL-8 mRNA, which suggested tran-
scriptional regulation of the cytokine (Figure 3C, right).
To determine whether secreted IL-8 activated JAK2/STAT5
in breast cancer cells, we assessed whether these cells express
its cognate receptors, CXCR1 andCXCR2. Therewas a 2.8- to 3-
fold higher expression of CXCR1 than CXCR2 on both MDA468
and MDA231 LM2 cells (Figure S3A). Stimulation with cytokines.
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Figure 2. Cotargeting PI3K/mTOR and JAK2 Reduces Cell Viability
(A) Immunoblots of lysates of breast cancer cells after 20 hr of treatment with BEZ or BSK alone or in combination. DMSO, lysates of cells treated with 0.005%
DMSO for 20 hr.
(B) Bar graphs showing the mean percentage of cell viability measured by the WST-1 assay (upper left) and by Trypan Blue cell counts (upper middle) of
cell lines grown under 0.5% serum and treated with 300 nM BEZ and/or 350 nM BSK for 72 hr. Bar graph representing colony formation frequencies of cells
treated as indicated (upper right). Immunoblots of lysates from the same cell lines after 8 hr of treatment as indicated are shown in the lower panel. Data are
means ± SEM (n = 4, *p < 0.05).
(C) Bar graphs showing the mean percentage of apoptotic and dead cells after 48 hr of treatment as measured by FACS analysis of AnnexinV and PI stained cells
treated with 300 nM BEZ and/or 350 nM BSK as indicated (left panel). Immunoblots of lysates from cells treated with 300 nM BEZ and/or 350 nM BSK for 24 hr
(right panel). Data are means ± SEM (n = 5, *p < 0.05).
See also Figure S2.
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JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibitionknown to activate JAK2/STAT5 in different cellular settings re-
vealed strong activation of JAK2/STAT5 by IL-8 (Figure S3B).
Chemotherapy can induce senescence-associated secretion
of cytokines, including IL-8 (Rodier and Campisi, 2011). We
tested whether BEZ235 induces senescence by treating cells
with the inhibitor for 5 days and then stained for b-galactosidase
activity. We found that BEZ235 did not induce senescence in
breast cancer cell lines (Figure S3C).
Activation of JAK2/STAT5/IL-8 Is Frequent in
BEZ235-Insensitive TNBC Models
To assess the generality of our findings, we treated a panel of
18 breast cancer lines with BEZ235 and measured JAK2/CanSTAT5 activation and IL-8 secretion. TNBC lines showed
a higher baseline of pJAK2 and pSTAT5 than luminal cell lines
and enhanced secretion of IL-8. Importantly, pJAK2, pSTAT5,
and/or IL-8 secretion increased in 11 of the 18 lines upon
BEZ235 treatment. Notably, the significant correlation found
between BEZ235-triggered activation of JAK2 and IL-8 secre-
tion strongly supports the generality of the crosstalk demon-
strated between PI3K/mTOR and JAK2/STAT5/IL-8 in TNBC
(Figure 3D; Table S1).
Our data suggested that activation of JAK2/STAT5 counter-
acts BEZ235-mediated reduction in cell viability (see Figures
2B and S2D). Therefore, we asked whether the upregulation
of JAK2/STAT5/IL-8 upon BEZ235 treatment is correlated withcer Cell 22, 796–811, December 11, 2012 ª2012 Elsevier Inc. 799
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Figure 3. Dual PI3K/mTOR Inhibition Induces IL-8 Secretion in BEZ235-Insensitive Breast Cancer Cells
(A) Immunoblots of lysates from cells treated for 1 hr with conditioned media from cells treated with 300 nM BEZ for 20 hr. Lysates of cells treated with medium
containing BEZ (SN BEZ ctrl) were used as a control for the BEZ present in the conditioned media. ELISA data are means ± SD (n = 3).
(B) Cytokine arrays showing expression of the indicated cytokines in supernatants of cells treated with 300 nM BEZ for 24 hr (upper panel) or in tumors frommice
treated with 30 mg/kg BEZ for 10 days (lower panel). Mouse MIP2 is the functional homolog of human IL-8.
(C) Bar graphs showing the levels of IL-8 secretion (left panel) andmRNA (right panel) in cells treated with 300 nMBEZ as indicated. Levels of IL-8 were measured
by ELISA and RT-qPCR and are shown as means ± SEM (n = 4, *p < 0.05).
(D) Scatter plot showing correlation in breast cancer lines between IL-8 secretion and the ratios of pJAK2/JAK2 upon BEZ treatment for 20 hr and 8 hr,
respectively. Grey: luminal-like lines. Black: TNBC lines. Values from BEZ-treated relative to DMSO cells are shown (see also Table S1). Data are means of three
independent experiments (n = 16, correlation = 0.77, p = 0.0006).
Cancer Cell
JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibition
800 Cancer Cell 22, 796–811, December 11, 2012 ª2012 Elsevier Inc.
Cancer Cell
JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibitionthe sensitivity of cell lines to this inhibitor. Comparison of pJAK2
and IL-8 levels in 12 breast cancer cell lines to their reported
sensitivity to BEZ235 (Brachmann et al., 2009) revealed higher
activation of JAK2 and upregulation of IL-8 in BEZ235-insensi-
tive than in sensitive lines (Figure 3E). Combined inhibition of
PI3K/mTOR and JAK2 reduced the viability of BEZ235-insensi-
tive lines further, underscoring the relevance of the crosstalk
between the PI3K and JAK2/STAT5 pathways for the response
to PI3K/mTOR inhibition (Figure 3F).
Biphasic Activation of JAK2/STAT5 upon PI3K/mTOR
Inhibition
To test whether IL-8 is necessary and sufficient for activation of
JAK2/STAT5, we blocked CXCR1, and thus IL-8 signaling, at
different time points after BEZ235 treatment using a CXCR1-
neutralizing antibody. As predicted, blocking CXCR1 reduced
pFAK (Figure S4A) (Ginestier et al., 2010). More importantly,
CXCR1 inhibition efficiently blocked the induction of pJAK2/
pSTAT5 after 20 hr of BEZ235 treatment but, surprisingly, failed
to prevent activation after only 8 hr (Figure 4A). Furthermore, we
found that depletion of CXCR1 by siRNA did not affect BEZ235-
induced upregulation of pJAK2/pSTAT5 after 8 hr of treatment,
but abrogated it after 20 hr of treatment (Figures S4B and
S4C). This suggests a biphasic activation of JAK2/STAT5 upon
PI3K/mTOR inhibition, the first phase being IL-8/CXCR1-inde-
pendent and the second being IL-8/CXCR1-dependent. This is
in line with the increase in IL-8 secretion observed after 20 hr
of BEZ235 treatment (Figure 3C).
These results raised the question of how JAK2 and STAT5 are
activated at earlier time points of PI3K/mTOR inhibition.
Epidermal growth factor receptor (EGFR) activates JAK2 in
some models (Yamauchi et al., 1997) and, as EGFR has been
shown to be activated upon PI3K/mTOR inhibition (Muranen
et al., 2012), we tested whether EGFR is important for the activa-
tion of JAK2/STAT5 upon PI3K/mTOR blockade. Cells were
treated for 8 hr with BEZ235 and/or the EGFR inhibitor AEE788
(Traxler et al., 2004). Although inhibition of EGFR indeed reduced
pSTAT5 levels, it did not block the upregulation following
BEZ235 treatment (Figure S4D).
Components of the insulin receptor (IR)/IGF-1R signaling
pathways have been shown to interact with JAK/STAT (Gual
et al., 1998; Le et al., 2002) and the same pathways are upregu-
lated and activated upon mTOR (Haruta et al., 2000) and AKT
inhibition (Chandarlapaty et al., 2011). Hence, there appears to
be crosstalk between activation of the IR/IGF-1R pathways
induced by AKT/mTOR inhibition and JAK2/STAT5. Indeed, IR
and IGF-1R were upregulated and underwent increased phos-
phorylation upon BEZ235 treatment for 8 and 20 hr; IRS1 accu-
mulated and showed increased phosphorylation after 2–20 hr of
treatment (Figure 4B).
These data showed that accumulation of IRS1 preceded and
possibly accounted for the first wave of pJAK2/pSTAT5 activa-
tion. Coimmunoprecipitation studies revealed association of(E) Scatter plots showing breast cancer lines as in (D), depicted based on the ratio
treatment, and sensitivity toward BEZ. The horizontal lines represent mean value
(F) Bar graphs showing the mean percentages of cell viability as measured by th
lines (right panel) grown under 0.5% serum and treated with 300 nM BEZ and/or
See also Figure S3 and Table S1.
Canboth JAK2 and STAT5 with IRS1 in BEZ235- as well as DMSO-
treated cells, but only weak association of JAK1 and STAT3
with IRS1 (Figure 4C). Our data thus showed that JAK2/STAT5
bind to IRS1 but not whether binding accounts for the first phase
of BEZ235-induced pJAK2/pSTAT5. To address this question,
we depleted IRS1 prior to BEZ235 treatment and found that
this abrogated JAK2/STAT5 activation (Figure 4D, upper panel);
thus, the first phase of JAK2/STAT5 activation appears to be
IRS1-dependent.
Next, we examined whether the first phase of JAK2/STAT5
activation accounts for IL-8 upregulation and secretion by
measuring IL-8 levels in the supernatant of cells expressing
IRS1 siRNA and which were also treated with BEZ235. Depletion
of IRS1 abrogated secretion of IL-8 upon BEZ235 treatment
(Figure 4D, lower panel). In addition, knockdown of STAT5 or
inhibition of JAK2 decreased BEZ235-evoked IL-8 transcription
and secretion (Figures 4E and 4F), demonstrating that IL-8 upre-
gulation is JAK2/STAT5-dependent.
Taken together, these data show that BEZ235-evoked activa-
tion of IR/IGF-1R/IRS1 triggered phosphorylation of JAK2/
STAT5, which led to upregulation of IL-8 and induced the second
phase of JAK2/STAT5 activation, thus completing a positive
feedback loop.
Combined Inhibition of PI3K/mTOR and JAK2 Reduces
Tumor Growth
That PI3K/mTOR inhibition triggers activation of JAK2/STAT5
and upregulation of IL-8 raises the possibility that this feedback
loop could reduce the efficacy of PI3K/mTOR inhibitors in vivo.
Using two independent orthotopic xenograft models and one
orthotopic allograft model of breast cancer, we examined
whether interfering with this feedback loop by inhibiting JAK2
affects the growth of tumors. Palpable tumors were treated
with BEZ235 and/or inducible shRNA targeting JAK2, or with
BEZ235 and/or NVP-BSK805. Single inhibition of JAK2 had no
impact on tumor growth (Figures 5A–5D, left panels). However,
tumor growth was reduced by treatment with BEZ235 and
a synergistic reduction in tumor growth was seen when
BEZ235 was combined with JAK2 inhibition (Figures 5A–5D,
left panels). Tumor weight at the end of the treatments mirrored
differences in tumor volume (Figures S5A and S5B). Notably,
a synergistic effect was observed at lower doses of BEZ235
and NVP-BSK805when combined than as individual treatments.
Lower doses of the inhibitors were applied to avoid possible
side-effects and potential drug-drug interaction of the combina-
tion. Indeed, there was no significant reduction in mouse body
weight after any of the treatments (Figure S5C).
We then assessed the efficiency of PI3K/mTOR and JAK2 inhi-
bition (Figures 5A–5D, right panels, and S5D). Both BEZ235 and
NVP-BSK805 potently blocked their targets, as judged by the
levels of pAKT/pS6 and pSTAT5, respectively. In addition,
consistent with our previous results, pSTAT5 was strongly upre-
gulated by BEZ235 treatment in all models, cleaved PARPs of pJAK2/JAK2 (left panel), the levels of secreted IL-8 (right panel) upon BEZ
s (n = 3, *p < 0.05).
e WST-1 assay of two BEZ-insensitive lines (left panel) and two BEZ-sensitive
350 nM BSK for 72 hr. Data are means ± SEM (n = 4, *p < 0.05).
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Figure 4. Cotargeting PI3K/mTOR Induces Biphasic Activation of JAK2/STAT5
(A) Immunoblots of lysates from cells treated with DMSO or 300 nM BEZ alone or in combination with IgG or a CXCR1-blocking antibody added 1 hr before lysis.
The numbers indicate the ratios of pSTAT5/STAT5 as measured by densitometry. ELISA data are means ± SD (n = 3).
(B) Immunoblots of lysates from cells treated with 300 nM of BEZ as indicated.
(C) Immunoprecipitation (IP) and immunoblotting of lysates from cells treated with DMSO or 300 nM BEZ for 8 hr. WCL, whole cell lysates.
(D) Immunoblots of lysates from cells in which IRS1was depleted by siRNA before treatmentwith DMSOor 300 nMBEZ for 8 hr. ELISA data aremeans ±SD (n = 3)
(upper panel). Bar graphs showing the levels of IL-8 secretion upon treatment with 300 nMBEZ for 20 hr (lower panel). Levels of IL-8 weremeasured by ELISA and
are shown as means ± SEM (n = 4, *p < 0.05).
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JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibitionincreased in the combination treatment regime only, and prolifer-
ation declined in the BEZ235 and combination treatment groups
(Figures 5A–5D, right panels, and S5E).
Combined Inhibition of PI3K/mTOR and JAK2 Reduces
Metastasis
Metastasis is a multistep process that culminates with growth of
tumor cells at distant sites. We analyzed the effects of targeting
PI3K/mTOR alone or in combination with JAK2 inhibition on
metastasis in mice injected with GFP-expressing MDA231 LM2
or 4T-1 metastatic cell lines. FACS analysis showed a slight
reduction in the number of circulating GFP+ tumor cells (CTC)
in the blood of mice following BEZ235 treatment, but a dramatic
reduction after JAK2 inhibition or combined inhibition of
PI3K/mTOR and JAK2 (Figure S5F). To test whether the reduc-
tion in CTCs was a consequence of reduced primary tumor
volume, we calculated the CTC index upon PI3K/mTOR
or JAK2 inhibition alone or in combination (Figure 5E). The
CTC index was not affected by BEZ235 alone, but was signifi-
cantly reduced by the combination of PI3K/mTOR and JAK2
inhibition or by JAK2 inhibition alone (Figure 5E). Next, we
analyzed effects of the treatment on lung metastasis (Figure 5F).
Importantly, although BEZ235 alone had no effect, the combina-
tion of BEZ235 and JAK2 inhibition or JAK2 inhibition alone
reduced the metastatic index in all models (Figures 5G, 5H,
S5G, and S5H).
To test whether this reduction in metastasis was due to cell-
autonomous and/or noncell autonomous effects, we treated
mice bearing tumors expressing shJAK2 either with vehicle or
NVP-BSK805. No further reduction in the lung metastatic index
was observed compared with single inhibition of JAK2 (Fig-
ure S5I). Thus, NVP-BSK805 mainly reduces metastatic burden
in a cell-autonomous fashion.
Inhibition of JAK2 Blocks the BEZ235-Evoked
IL-8/CXCR1 Pro-Metastatic Axis
To elucidate the mechanism underlying the reduction in metas-
tasis observed upon combined PI3K/mTOR and JAK2 inhibition,
we evaluated the impact of BEZ235 or NVP-BSK805 or their
combination on IL-8 transcription and secretion in vitro and
in vivo. Basal levels of active JAK2/STAT5 were higher in the
highly metastatic breast cancer sublines 4T-1 and MDA231
LM2 than in the cognate poorly metastatic parental lines
168FARN and MDA231, respectively (Figure S6A). Consistently,
the metastatic MDA231 LM2 cells exhibited stronger transcrip-
tion and secretion of IL-8 (Figure S6B) and higher expression of
the IL-8 surface receptor CXCR1 (Figure S6C) than the parental
MDA231 cell line. Moreover, we found a correlation between
IL-8 secretion, the triple-negative subtype and invasiveness in
luminal and TNBC lines (Neve et al., 2006) (Figure S6D). We
then compared CXCR1 expression levels in invasive, BEZ235-
resistant cell lines and in noninvasive, BEZ235-sensitive cell(E) Bar graphs showing the levels of IL-8 secretion (left panel) and mRNA (right pa
Levels of IL-8 were measured by ELISA and RT-qPCR, and are shown as means ±
see Figure S2B.
(F) Bar graphs showing the levels of IL-8 secretion (left panel) and mRNA (right pan
8 hr (right panel). Levels of IL-8 were measured by ELISA and RT-qPCR, and are
See also Figure S4.
Canlines. A striking correlation between CXCR1 expression and the
invasive, BEZ235-resistant phenotype was observed, suggest-
ing the involvement of CXCR1 signaling in invasion and adaptive
resistance toward BEZ235 (Figure S6E; see also Figure 3E).
Given that IL-8 was induced by PI3K/mTOR inhibition and
reduced by blockade of JAK2 in vitro (Figure 4F), we examined
whether this was also the case in vivo. We found IL-8 to be
elevated in tumors (Figure 6A) and in the plasma of BEZ235-
treated mice (Figure 6B); this was reduced by inhibition of
JAK2 or both JAK2 and PI3K/mTOR. To address the conse-
quences of increased IL-8 secretion, we inhibited the IL-8
receptor in vitro using a CXCR1-blocking antibody and in vivo
by Repertaxin, a noncompetitive allosteric CXCR1/2 inhibitor
(Bertini et al., 2004). Combined inhibition of IL-8 and PI3K/
mTOR reduced invasion as well as the CTC and metastatic
indices. Notably, inhibition of IL-8 did not enhance the effects
of JAK2 inhibition in these assays, further supporting roles for
IL-8/CXCR1/JAK2 in invasion, tumor seeding and metastasis
(Figures 6C–6E and S6F).
IL-8 and CXCR1 have been shown to be important for tumor-
initiating cells (Ginestier et al., 2010). We confirmed this observa-
tion using limiting dilution transplantation of CXCR1+ and
CXCR1 cell populations (Figure S6G). FACS analysis of disso-
ciated tumor cells, CTCs and lungs from vehicle-treated mice
bearing xenografts revealed that only 3% of primary tumor cells
were CXCR1+ but CTCs were almost exclusively CXCR1+ (96%).
Furthermore, 20.5% of lung metastases cells expressed the
receptor at high levels (Figure 6F). In the primary tumor, the
CXCR1+ population increased 1.9-fold upon PI3K/mTOR inhibi-
tion and decreased 2-fold upon inhibition of JAK2 alone or in
combination with PI3K/mTOR inhibition (Figure 6G). Notably,
JAK2 inhibition preferentially triggered cell death in the
CXCR1+ subpopulation (Figure 6H). Consistently, limiting
dilution transplantation experiments revealed a decrease in
tumor-initiating cell frequency upon JAK2 inhibition alone or in
combination with PI3K/mTOR inhibition (Figures 6I and S6H).
Collectively, our data demonstrate that inhibition of the JAK2/
STAT5/IL-8 positive feedback loop triggered by PI3K/mTOR
blockade reduced tumor growth and seeding as well as lung
metastasis due to its impact on the tumorigenic and metastatic
CXCR1+ subpopulation of cancer cells. This strongly suggests
that the combination of PI3K and JAK2 inhibitors may be more
effective in the neoadjuvant setting than either inhibitor alone.
PI3K/mTOR Inhibition Activates JAK2/STAT5/IL-8
in Primary Human Breast Tumors
Wenext assessed whether interfering with PI3K/mTOR in human
primary breast tumors also triggered a JAK2/STAT5/IL-8 positive
feedback loop. BEZ235 treatment of human primary TNBCs
grown as xenografts increased pJAK2 and pSTAT5 (Figure 7A).
Moreover, IL-8 in the tumors and in the plasma of the mice
also increased upon treatment with BEZ235 (Figure 7B). Thesenel) upon treatment with 300 nM BEZ for 20 hr (left panel) or 8 hr (right panel).
SEM (n = 4, *p < 0.05). For immunoblots of lysates from siSTAT5 depleted cells
el) upon treatment with 300 nM BEZ and/or 350 nM BSK for 20 hr (left panel) or
shown as means ± SEM (n = 4, *p < 0.05).
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Figure 5. Cotargeting PI3K/mTOR and JAK2/STAT5 Reduces Primary Tumor Growth, Tumor Seeding, and Metastasis
(A–D) Growth curves of tumors and immunoblots of tumor lysates frommice treated with VHC, 30 mg/kg BEZ, 120 mg/kg BSK, or 25 mg/kg BEZ and 100 mg/kg
BSK. In (C) JAK2 was depleted in tumors by doxycycline (dox) administration to induce expression of a JAK2-targeting shRNA (shJAK2). shNT, nontargeting
shRNA. Injection refers to orthotopic cell injection and the arrows indicate initiation of treatment and/or administration of dox. Immunoblotting was performed on
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JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibitiondata showed that the identified positive feedback loop mediated
by PI3K/mTOR inhibition is also active in human primary breast
tumors and suggest that targeting JAK2 in addition to PI3K/
mTOR should block this resistance mechanism and enhance
the efficacy of the inhibitors.
Combined PI3K/mTOR and JAK2 Inhibition Increases
Survival in a Preclinical Setting
To leverage the mechanistic understanding gained from our
experiments into a preclinical setting and to assess the thera-
peutic relevance of our findings, we performed survival studies
using two different metastaticmodels.We treated tumor-bearing
mice with BEZ235 and/or NVP-BSK805 and scored the time at
which primary tumors reached 1 cm3 (event-free survival) (Fig-
ure 8A). To mimic the neoadjuvant setting, we treated tumor-
bearing mice with BEZ235 and/or NVP-BSK805, dissected the
primary tumors, treated mice again, and then monitored them
for signs of distress (overall survival) (Figure 8B). We found that
BEZ235 treatment reduced primary tumor volume in both
models and that JAK2 inhibition, although not affecting event-
free survival, significantly enhanced overall survival. Most impor-
tant, combination of BEZ235 and NVP-BSK805 enhanced
preclinical benefit in terms of both event-free and overall survival
of the animals.
DISCUSSION
Targeted anticancer drugs have greatly increased the hope of
more effective and better tolerated therapies. Although some
targeted therapies constitute a breakthrough and have changed
the treatment landscape, in numerous cases they have not yet
lived up to their promise, with the sobering realization that resis-
tance can emerge within a few months (Engelman et al., 2008;
Solit and Rosen, 2011). Delineation of these resistance mecha-
nisms will pave the way for rationally designed and hopefully
long-lasting combinations of targeted therapies. In the present
study, we found that PI3K/mTOR inhibition elicits a positive feed-
back response in TNBC that leads to biphasic activation of
JAK2/STAT5 and IL-8 secretion, thus dampening the response
to the PI3K inhibitors. Our data suggest the following model (Fig-
ure 8C): in the untreated tumor (left), PI3K and mTOR are active
and support survival and proliferation; JAK2/STAT5 signaling
induces IL-8 production and contributes to metastasis. Upon
PI3K/mTOR inhibition (middle), IRS1 as well as IGF-1R and IR
accumulate and lead to the first wave of JAK2/STAT5 hyperacti-tumors harvested after 14 days of treatment for MDA468, 10 days of treatment
volume ± SEM (three independent experiments, total n = 4–8, *p < 0.05, **p < 0.
(E) Bar graphs showing the circulating tumor cell (CTC) index. The number of CT
21 days (MDA231 LM2) or 5 days (4T-1) after initiation of the treatment as in (B)–(D
100 ml peripheral blood by tumor volume. Data represent the means ± SEM (for MD
the other models in three independent experiments, with a total n = 7 mice; *p <
(F) Drawings of the experimental setup.
(G) Representative IHC pictures of lungs from VHC-, BEZ-, BSK- and BEZ/BSK-
MDA231 LM2-bearing animals, treated as described in (B) and (F). Scale bar re
treated as described in (D) and (F). Arrows indicate metastases; the images to the
(H) Bar graphs showing the metastatic index of mice treated as in (B–D) calcula
volume. Data are means ± SEM (for MDA231 LM2 shJAK2 from two indepen
experiments, total n = 10, *p < 0.05).
See also Figure S5.
Canvation. JAK2/STAT5 activity in turn restores pAKT and blocks
cell death, thereby offsetting the impact of BEZ235 on cell
viability. JAK2/STAT5 activation also leads to an increase in IL-
8 secretion, which activates the second wave of JAK2/STAT5
and completes the feedback loop. Moreover, IL-8 increases
the relative number of CXCR1+ cells. The efficacy of PI3K/
mTOR inhibition can be improved dramatically by simultaneous
JAK2 inhibition (right), which reduces the viability of CXCR1+
tumor-initiating cells, the number of CTCs, and metastatic
spread as well as increase the overall survival of the animals.
Identification of a Multimodal Mechanism of Resistance
to PI3K/mTOR Inhibition
Mechanisms of resistance to targeted therapy often involve
mutation of the target (Engelman and Ja¨nne, 2008), reactivation
of the targeted pathway (vertical resistance) (Chandarlapaty
et al., 2011; Engelman et al., 2007), or activation of alternative
survival pathways (horizontal resistance) (Turke et al., 2010).
Activation of the PI3K pathway accounts for vertical and hori-
zontal resistance to several targeted therapies, including
inhibitors of EGFR, ERBB2, NOTCH, and MEK1 (Berns et al.,
2007; Engelman et al., 2007; Palomero et al., 2007; Wee
et al., 2009). But how does resistance to PI3K pathway inhibi-
tion occur? Notably, all reported mechanisms leading to
escape from inhibition of this pathway comprise vertical resis-
tance. Indeed, treatment with mTOR or AKT inhibitors may
lead to reactivation of upstream components of the PI3K
pathway (Chandarlapaty et al., 2011; Haruta et al., 2000; O’Re-
illy et al., 2006).
In the present study, we have uncovered a multimodal mech-
anism of resistance to targeting PI3K/mTOR. Biphasic activation
of JAK2/STAT5 stifles the actions of PI3K/mTOR inhibition by re-
activating AKT and increasing cell survival (vertical resistance),
while at the same time increasing the systemic levels of the
pro-metastatic cytokine IL-8 (horizontal resistance).
As expected, vertical cotargeting of the PI3K/mTOR pathway
using dual inhibitors circumvented the IR/IGF-1R/IRS1-evoked
reactivation of PI3K arising after mTOR inhibition, which most
likely accounts for the limited success of rapalogs as single-
agent anticancer therapies. Nevertheless, although dual PI3K/
mTOR inhibition reduces reactivation of PI3K, the IR/IGF-1R/
IRS1 axis remains active. The consequences of the sus-
tained activity of this axis on other pathways and on the sensi-
tivity to dual PI3K/mTOR inhibitors remain ill-defined. Our
findings that PI3K/mTOR inhibition-mediated reactivation offor MDA231 LM2, and 6 days of treatment for 4T-1. Results are mean tumor
01).
Cs was measured by FACS analysis of GFP+ cells in tail vein blood performed
). The CTC index was calculated by dividing the total number of GFP+ CTCs per
A231 LM2 shJAK2 in two independent experiments, total of n = 4mice, and for
0.05).
treated animals. Left panel: H&E- (left) and Vimentin-(right) stained lungs from
presents 250 mm. Right panel: H&E-stained lungs from 4T-1-bearing animals,
right are magnifications of single metastatic foci. Scale bar represents 200 mm.
ted by dividing the total number of visible lung metastases nodules by tumor
dent experiments, total n = 4, for the other models from three independent
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Figure 6. PI3K/mTOR Inhibition Increases, whereas JAK2 Inhibition Blocks IL-8 Secretion and Reduces the Tumor-Initiating CXCR1+
Subpopulation
(A) Bar graphs showing IL-8 levels measured by ELISA (left andmiddle panels) or quantification of dots of cytokine arrays (right panel) from tumors of mice treated
as in Figures 5A–5D. Data are means ± SEM (n = 3–8, *p < 0.05).
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Figure 7. BEZ235 Treatment Activates
JAK2/STAT5 and IL-8 Secretion in Primary
Human TNBC Xenografts
(A) Immunoblots of lysates from primary TNBC
xenografts treated for 4 days with 30 mg/kg BEZ
or VHC. ELISA data are means ± SD (n = 3).
(B) Bar graphs showing IL-8 levels measured by
ELISA in the dissected tumors from or in the
plasma of mice at day 3 of treatment with
30 mg/kg BEZ or VHC. Data are means ± SEM
(n = 3–4, *p < 0.05).
Cancer Cell
JAK2/STAT5 Activation Dampens PI3K/mTOR InhibitionIR/IGF-1R/IRS1 induces a first wave of active JAK2/STAT5,
which in turn contributes to rephosphorylation of AKT, shed
light on this question. We further found that BEZ235 reduces
the expression of the AKT Ser473 phosphatase PHLPP and
that it inefficiently targets the mTORC2 complex. Genetic inhibi-
tion of mTORC2 blocked the recovery of pS473 AKT upon treat-
ment with BEZ235, consistent with previous studies showing
that inhibition of S6K-induced mTORC2/AKT (Dibble et al.,
2009). These different feedback mechanisms may explain the
limited efficacy of dual PI3K/mTOR inhibition in some cancer
models. These results and our observation that individual
PI3K or mTOR inhibition also causes JAK2/STAT5 activation
raise the possibility that other inhibitors of the PI3K pathway
may elicit similar crosstalk.(B) Bar graphs showing IL-8 levels measured by ELISA in plasma of mice bearing tumors treated as in Figure
(C) Bar graphs showing relative invasion of MDA231 LM2 cells seeded on Matrigel-coated Boyden cham
and/or CXCR1 blocking antibody. Invasion was assessed after 48 hr. Data represent relative invasion values
(n = 4, *p < 0.05).
(D) Growth curves of tumors from mice treated with VHC, 30 mg/kg BEZ, 120 mg/kg BSK, 20 mg/kg Repert
20 mg/kg Rep. Injection refers to orthotopic cell injection and the arrow indicates initiation of treatment. Data
(E) Bar graphs showing CTC (upper panel) and lung metastatic (lower panel) indices of mice treated as in Figu
means ± SEM (n = 3–4, *p < 0.05).
(F) Upper: representative images of FACS dot plots of CXCR1-stained tumors, CTCs and lungs. Lower: bar gra
are means ± SEM (n = 6).
(G) Bar graph showing percentages of CXCR1+ cells in MDA231 LM2 tumors of mice treated as in Figure 5B
(H) Representative dot plot of FACS analyses performed on CXCR1- (upper panel), AnnexinV-, and PI-stai
inhibitors as in Figure 2C. Bar graphs show the mean percentages of apoptotic and dead cells after 48 hr of t
(I) Upper: drawing of the experimental setup. Mice bearing MDA231 LM2 tumors were treated as in Figure
retransplanted at different dilutions. Cell viability prior to retransplantation was analyzed by PI-FACS staining
(data not shown). Lower: bar graph showing the TIC frequencies after treatment as in Figure 5B. Data are me
total n = 7 mice, *p < 0.05, ***p < 0.0001.
See also Figure S6.
Cancer Cell 22, 796–811, DCotargeting PI3K/mTOR and JAK2
Increases Cell Death and Reduces
Tumor Growth
The PI3K and JAK2 pathways activate the
prosurvival protein MCL1 and suppress
the pro-apoptotic protein BIM at the tran-
scriptional and posttranslational levels
(Ewings et al., 2007; Opferman, 2006).
We found that combined inhibition of
PI3K/mTOR and JAK2 activates BIM
and concomitantly downregulates
MCL1, causing an increase in apoptosis.
Notably, this latter effect was not
observed upon single inhibition of PI3K/
mTOR or JAK2/STAT5, suggesting thatactivation of either pathway prevents cell death. Combined
PI3K and MEK inhibition similarly decreased MCL1 and
increased BIM, thereby triggering cell death in EGFR mutant
lung cancer (Faber et al., 2009). Themoderate levels of cell death
detected upon combined PI3K/mTOR and JAK2 inhibition, both
in vitro and in vivo, can be explained by the fact that cell death
was mainly induced in the small subpopulation of CXCR1+
tumor-initiating cells.
Genetic depletion of JAK2 after overt tumor development was
shown to have no effect on tumor growth (Sakamoto et al., 2009).
Similarly, we found no effect of single JAK2 inhibition on tumor
growth. However, (Hedvat et al., 2009; Xin et al., 2011) showed
that a different JAK inhibitor reduced primary tumor growth of
xenografts of MDA468 and 4T-1, two cell lines that we alsos 5A–5C. Data are means ± SEM (n = 4, *p < 0.05).
bers and treated with 300 nM BEZ, 350 nM BSK
normalized to cell number and are means ± SEM
axin (Rep), or 25 mg/kg BEZ, 100 mg/kg BSK and
are mean tumor volume ± SEM (n = 4–8, *p < 0.05).
re 5F. Rep was administered at 20 mg/kg. Data are
phs showing the percentage of CXCR1+ cells. Data
. Data are means ± SEM (n = 4–6, *p < 0.05).
ned (lower panel) MDA231 LM2 cells treated with
reatment. Data are means ± SEM (n = 4, *p < 0.05).
5B. The tumors were dissected, dissociated, and
and was found to be equal in all treatment groups
an estimates from three independent experiments,
ecember 11, 2012 ª2012 Elsevier Inc. 807
Figure 8. Cotargeting PI3K/mTOR and
JAK2 Increases Event-Free and Overall
Survival in TwoModels of Metastatic Breast
Cancer
(A) Upper: drawing of the experimental setup.
Lower: Kaplan-Meier survival curves of MDA231
LM2 (left) and 4T-1 (right) tumor-bearing mice
treated with BEZ and/or BSK as in Figures 5B and
5D. An event was scored when a tumor reached
1 cm3 (n = 4, *p < 0.05, **p < 0.01).
(B) Upper: drawing of the experimental setup.
Lower: Kaplan-Meier survival curves of MDA231
LM2 (left) and 4T-1 (right) tumor-bearing mice
treated with BEZ and/or BSK as in Figures 5B
and 5D. An event was scored when a mouse
showed any sign of distress; (n = 4, *p < 0.05,
**p < 0.01).
(C) Schematics illustrating the identified positive
feedback loop triggered by inhibition of PI3K/
mTOR and offset by JAK2/STAT5 inhibition.
Upper: effects of PI3K/mTOR inhibition and/or
JAK2 inhibition at the cellular level. Lower: effects
of PI3K/mTOR and/or JAK2 inhibition at the
tumor level.
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JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibitionused in the present study. This inhibitor (Hedvat et al., 2009)
displayed a spectrum of JAK kinase selectivity different to
NVP-BSK805, which is biased toward JAK2 within the JAK
family (Baffert et al., 2010). Different inhibitors also display diver-
gent spectra of overall kinase selectivity, which may also
account for some of the tumor growth effects observed by (Hed-
vat et al., 2009). Of note, the focus of some of the other studies808 Cancer Cell 22, 796–811, December 11, 2012 ª2012 Elsevier Inc.has been on oncogenic STAT3 signaling
in breast cancer models (Hedvat et al.,
2009; Marotta et al., 2011), whereas our
present work has revealed an important
role for JAK2/STAT5 signaling. RNAi
experiments in our models showed that
JAK2 is required for STAT5 phosphoryla-
tion, whereas JAK1 predominantly sig-
nals to STAT3. Hence, dual JAK1/2 inhib-
itors may have additional antitumor
effects due to suppression of both
STAT3 and STAT5 phosphorylation.
Inhibition of PI3K/mTOR and JAK2
or JAK2 Alone Reduces Metastasis
and Increases Overall Survival
Consistent with the multimodal nature
of the identified feedback, cotargeting
PI3K/mTOR and JAK2/STAT5 also
reduced tumor seeding and metastasis.
These effects can be explained by the
fact that targeting JAK2 abrogated this
feedback loop, decreasing STAT5 activa-
tion and IL-8 transcription and secretion,
which culminated in death of the
CXCR1+ cells. The observation that
CXCR1+ cells were a minor subpopula-
tion in the primary tumor but constitutethe majority of CTCs and 20% of lung metastases raises the
intriguing possibility that CXCR1 and its associated downstream
signaling are crucial for intravasation and/or survival of the cells
in the periphery, but less critical once cells have reached the
metastatic site. Consistently, IL-8 inhibition alone or in combina-
tion with PI3K/mTOR inhibition reduced tumor seeding and
metastasis. Indeed, IL-8 has been shown to play crucial roles
Cancer Cell
JAK2/STAT5 Activation Dampens PI3K/mTOR Inhibitionin the stimulation of tumor-initiating cells, invasion, and metas-
tasis (Charafe-Jauffret et al., 2009; Ginestier et al., 2010; Waugh
and Wilson, 2008), and a role for JAK2 in cells with the cancer
stem cell phenotype has also been suggested (Marotta et al.,
2011).
To gain insights into a potential clinical benefit of combined
inhibition of PI3K/mTOR and JAK2, we performed survival
studies in a preclinical setting. We found that single JAK2 inhibi-
tion increased overall survival, while having no benefit on event-
free survival. Notably, combination of BEZ235 and NVP-BSK805
increased both event-free and overall survival of animals. Our
findings potentially have direct clinical implications, given that
26 PI3K pathway inhibitors are currently undergoing clinical
evaluation (Sheppard et al., 2012). These results urge assess-
ment of the activation of the JAK2/STAT5/IL-8 positive feedback
loop before therapy and/or upon PI3K inhibition, and the testing
of the efficacy of cotargeting PI3K/mTOR and JAK2 in TNBC and
other cancers.
EXPERIMENTAL PROCEDURES
Compounds
BEZ235, NVP-BSK805,NVP-BKM120, andRAD001were fromNovartis (Basel,
Switzerland). Repertaxin L-lysine salt was obtained from WuXi AppTec
(Shanghai,China).Daunorubicinwasobtained fromSigmaAldrich.Compounds
were prepared as 10 mM stock solutions in DMSO and stored protected from
light at 20C. NVP-BSK805 was freshly formulated in NMP/PEG300/Solutol
HS15 (5%/80%/15%) and BEZ235 in NMP/PEG300 (10%/90%), and both
were administered to mice by oral gavage at 10 ml/kg. Repertaxin was freshly
formulated in PBS and administered subcutaneously at 20 mg/kg.
Primary Human Breast Tumors
Primary breast cancer specimens were obtained from the consented patients:
two specimens were provided by the Cooperative Human tissue Network
which is funded by the National Cancer institute, and one was obtained at
and approved by the board of the Saint-Louis Clinic (France). All studies
were approved by the Ethikkommission beider Basel.
Animal Experiments
SCID/beige, SCID/NOD, and Balb/c mice (Jackson Laboratories) were used in
compliance with the Swiss laws on animal welfare and the animal protocols
were approved by the Swiss Cantonal Veterinary Office of Basel. For ortho-
topic engraftment of breast cancer cell lines, 1 3 106 MDA468, 1 3 106
MDA231 LM2, and 0.5 3 106 4T-1 or 4T-1-GFP cells were suspended in
a 100 ml mixture of Basement Membrane Matrix Phenol Red-free (BD Biosci-
ences) and PBS 1:1 and injected into mouse mammary gland. Primary breast
tumors were cut into 1 mm3 pieces and transplanted into mouse mammary
gland. Tumor-bearing mice were randomized based on tumor volume prior
to the initiation of treatment, which started when average tumor volume was
at least 100 mm3. BEZ235 and NVP-BSK805 were given orally on each of 6
consecutive days followed by 1 day without the drug; Repertaxin was admin-
istered daily. Expression of shRNAs was induced by adding doxycycline in the
drinking water (2 g/l in a 5% sucrose solution), which was refreshed every
48 hr. Tumors were measured every 3–4 days and tumor volumes calculated
by the formula 0.5 3 (larger diameter) 3 (smaller diameter)2. End point tumor
sizes were analyzed for synergism using the formula AB/C < A/C3 B/C, where
C is tumor volume VHC, A is tumor volume compound 1, B is tumor volume
compound 2, and AB is tumor volume combination (Clarke, 1997). For survival
studies, animals were sacrificed when tumors reached 1 cm3 or when they
showed any signs of distress (e.g., breathing disorders, weight loss, or
immobility).
Statistical Analysis
Each value reported represents the mean ± SEM of at least three independent
experiments. Data were tested for normal distribution and Student’s t test,CanANOVAs, or nonparametric Mann-Whitney U/Wilcoxon tests were applied.
To account for multiple comparisons, Tukey HSD and Wilcoxon tests were
performed. StatView 5.0.1 was used for Kaplan-Meier survival analysis and
log rank Mantel-Cox tests were applied to test statistical significance (SAS).
Programs JMP4 and JMP9 were used for all other statistical tests (SAS). The
p values < 0.05 were considered to be statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.10.023.
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